These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 23613370)

  • 1. [Investigation today for practice tomorrow].
    Klein H
    Dtsch Med Wochenschr; 2013 May; 138(18):933. PubMed ID: 23613370
    [No Abstract]   [Full Text] [Related]  

  • 2. [New, expensive antidiabetics for the treatment of type-2 diabetes--pro].
    Müller-Wieland D
    Dtsch Med Wochenschr; 2010 May; 135(18):922. PubMed ID: 20425678
    [No Abstract]   [Full Text] [Related]  

  • 3. [Obesity and diabetes mellitus: increasing problems call for increasing efforts].
    Nauck M
    Dtsch Med Wochenschr; 2010 May; 135(18):901. PubMed ID: 20425673
    [No Abstract]   [Full Text] [Related]  

  • 4. [Prevention and early therapy play too minor a role in our health care system].
    Rothe HJ
    Med Klin (Munich); 2003 Oct; 98 Suppl 1():22-3. PubMed ID: 14694840
    [No Abstract]   [Full Text] [Related]  

  • 5. Should future health-care costs be discounted? The case of diabetes in Australia.
    Scuffham PA
    Intern Med J; 2006 Mar; 36(3):148-9. PubMed ID: 16503948
    [No Abstract]   [Full Text] [Related]  

  • 6. [The German diabetes dilemma: DMP: insufficient management of the diabetic patient in general practice?].
    MMW Fortschr Med; 2005 Oct; 147(41):10. PubMed ID: 16270503
    [No Abstract]   [Full Text] [Related]  

  • 7. [Assessment of novel antidiabetic drugs in Germany. Do innovations still have a chance?].
    Gallwitz B
    MMW Fortschr Med; 2014 Jul; 156(13):57-60. PubMed ID: 25318228
    [No Abstract]   [Full Text] [Related]  

  • 8. [How AMOG limits the supply of diabetes drugs].
    Oberhofer E
    MMW Fortschr Med; 2015 Aug; 157(14):24. PubMed ID: 26289868
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting.
    Mittendorf T; Smith-Palmer J; Timlin L; Happich M; Goodall G
    Diabetes Obes Metab; 2009 Nov; 11(11):1068-79. PubMed ID: 19732121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [BOT with insulin glargine versus BOT with insulin detemir: comparison of treatment costs in type 2 diabetes based on the results of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study from the German Statutory Health Insurance perspective].
    Schädlich PK; Koltermann KC; Dippel FW; Hagenmeyer EG; Häussler B
    MMW Fortschr Med; 2010 Oct; 152 Suppl 3():89-95. PubMed ID: 21595152
    [No Abstract]   [Full Text] [Related]  

  • 11. [Disease management programs: data for the waste bin?].
    Martin S
    Dtsch Med Wochenschr; 2014 Jan; 139(1-2):17-8. PubMed ID: 24062020
    [No Abstract]   [Full Text] [Related]  

  • 12. [New, expensive antidiabetics for the treatment of type-2 diabetes--contra].
    Nawroth P
    Dtsch Med Wochenschr; 2010 May; 135(18):923. PubMed ID: 20425679
    [No Abstract]   [Full Text] [Related]  

  • 13. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economics of type 2 diabetes prevention.
    Kissimova-Skarbek K
    Przegl Lek; 2006; 63 Suppl 4():9-11. PubMed ID: 16967708
    [No Abstract]   [Full Text] [Related]  

  • 15. [Economics under scrutiny - experts discuss long acting insulin analogs].
    Pflege Z; 2011 Jan; 64(1):58. PubMed ID: 21305792
    [No Abstract]   [Full Text] [Related]  

  • 16. ["The Lantus case": and yet it does move (or not?)].
    Schöffski O
    Dtsch Med Wochenschr; 2010 Sep; 135(36):1755-6. PubMed ID: 20812163
    [No Abstract]   [Full Text] [Related]  

  • 17. ["DIabetes Versorgungs-Evaluation" (DIVE)--a national quality assurance initiative at physicians providing care for patients with diabetes].
    Danne T; Kaltheuner M; Koch A; Ernst S; Rathmann W; Rüssmann HJ; Bramlage P;
    Dtsch Med Wochenschr; 2013 May; 138(18):934-9. PubMed ID: 23613371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The obesity-driven rising costs of type 2 diabetes in Australia: projections from the Fremantle Diabetes Study.
    Davis WA; Knuiman MW; Hendrie D; Davis TM
    Intern Med J; 2006 Mar; 36(3):155-61. PubMed ID: 16503950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Costs of type 2 diabetes in Germany. Results of the CODE-2 study].
    Liebl A; Neiss A; Spannheimer A; Reitberger U; Wagner T; Görtz A
    Dtsch Med Wochenschr; 2001 May; 126(20):585-9. PubMed ID: 11402924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating the direct cost of Type 2 diabetes in Greece: the effects of blood glucose regulation on patient cost.
    Athanasakis K; Ollandezos M; Angeli A; Gregoriou A; Geitona M; Kyriopoulos J
    Diabet Med; 2010 Jun; 27(6):679-84. PubMed ID: 20546287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.